Literature DB >> 20233214

Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin.

Masaki Kitahara1, Tatsuro Kanaki, Itsuko Ishii, Yasushi Saito.   

Abstract

BACKGROUND AND
PURPOSE: It is not clear if the new 3-hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pitavastatin prevents atherogenesis by a direct effect. Statins have a cholesterol-lowering effect, so an accessible animal model of atherosclerosis showing only moderate hypercholesterolaemia as in humans, is needed. The effects of pitavastatin were evaluated on atherosclerotic lesions accumulating foam cells derived from macrophages, produced in rabbits with moderate hypercholesterolaemia by chronic inhibition of nitric oxide synthase (NOS). EXPERIMENTAL APPROACH: White New Zealand rabbits were fed a 0.2% cholesterol diet with the NOS inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) in the same diet. Pitavastatin (0.1 and 0.3 mg x kg(-1)) was given orally once a day for 8 weeks. The aortic arch and thoracic aorta were analysed by histochemistry and atherosclerotic lesions were quantified. The effect of pitavastatin on adhesion of THP-1 cells to endothelial cells, and cholesterol content in RAW264.7 cells incubated with oxidized or acetylated LDL were also investigated. KEY
RESULTS: Atherosclerotic lesions containing foam cells were induced in a model of atherosclerosis in rabbits with moderate hypercholesterolaemia by chronic inhibition of NOS. The area of atherosclerotic lesions was diminished by pitavastatin administration. The adhesion of THP-1 cells and cholesteryl ester content in RAW macrophages were decreased by pitavastatin treatment.
CONCLUSION: Atherosclerosis induced by chronic inhibition of NOS in moderately hypercholesterolaemic rabbits was suppressed by pitavastatin via inhibition of macrophage accumulation and macrophage foam cell formation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233214      PMCID: PMC2850399          DOI: 10.1111/j.1476-5381.2009.00630.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits.

Authors:  H Suzuki; H Yamazaki; T Aoki; J Kojima; T Tamaki; F Sato; M Kitahara; Y Saito
Journal:  Arzneimittelforschung       Date:  2000-11

Review 2.  Pleiotropic effects of statins and related pharmacological experimental approaches.

Authors:  M Alegret; J S Silvestre
Journal:  Methods Find Exp Clin Pharmacol       Date:  2006-11

Review 3.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

4.  Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts.

Authors:  S K Basu; J L Goldstein; G W Anderson; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

5.  A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.

Authors:  D Sumi; T Hayashi; N K Thakur; M Jayachandran; Y Asai; H Kano; H Matsui; A Iguchi
Journal:  Atherosclerosis       Date:  2001-04       Impact factor: 5.162

6.  Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity.

Authors:  Vaikom S Mahadevan; Malcolm Campbell; Pascal P McKeown; Ulvi Bayraktutan
Journal:  Cardiovasc Res       Date:  2006-06-27       Impact factor: 10.787

7.  The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.

Authors:  Shigeru Morikawa; Wakako Takabe; Chikage Mataki; Toru Kanke; Takahiro Itoh; Youichiro Wada; Akashi Izumi; Yasushi Saito; Takao Hamakubo; Tatsuhiko Kodama
Journal:  J Atheroscler Thromb       Date:  2002       Impact factor: 4.928

8.  Feeding rats the nitric oxide synthase inhibitor, L-N(omega)nitroarginine, elevates serum triglyceride and cholesterol and lowers hepatic fatty acid oxidation.

Authors:  A Khedara; Y Kawai; J Kayashita; N Kato
Journal:  J Nutr       Date:  1996-10       Impact factor: 4.798

9.  Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.

Authors:  O Hernández-Perera; D Pérez-Sala; J Navarro-Antolín; R Sánchez-Pascuala; G Hernández; C Díaz; S Lamas
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  8 in total

1.  Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model.

Authors:  Madhuvanthi A Kandadai; Jason Meunier; Christopher J Lindsell; George J Shaw; Mitchell S V Elkind
Journal:  Curr Neurovasc Res       Date:  2012-08       Impact factor: 1.990

2.  Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia.

Authors:  Bonpei Takase; Hidemi Hattori; Yoshihiro Tanaka; Masayoshi Nagata; Masayuki Ishihara
Journal:  Heart Asia       Date:  2013-09-13

3.  Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent.

Authors:  Mohamed Mahmoud El-Seweidy; Mervat El-Sayed Asker; Sameih Ibrahim Eldahmy; Hebatallah Husseini Atteia; Mohamed Ahmed Abdallah
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

Review 4.  Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 5.  Pleiotropic effects of pitavastatin.

Authors:  Jean Davignon
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

6.  Honokiol inhibits carotid artery atherosclerotic plaque formation by suppressing inflammation and oxidative stress.

Authors:  Yuan Liu; Peng Cheng; An-Hua Wu
Journal:  Aging (Albany NY)       Date:  2020-05-04       Impact factor: 5.682

7.  Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells.

Authors:  Kuang-Hsing Chiang; Wan-Li Cheng; Chun-Ming Shih; Yi-Wen Lin; Nai-Wen Tsao; Yung-Ta Kao; Chih-Ting Lin; Shinn-Chih Wu; Chun-Yao Huang; Feng-Yen Lin
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

8.  Effect of pitavastatin on vascular reactivity in hypercholesterolemic rabbits.

Authors:  Eros Antonio de Almeida; Michiko Regina Ozaki
Journal:  Arq Bras Cardiol       Date:  2014-07-09       Impact factor: 2.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.